This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:


peer-reviewed publication


WNT-pathway medulloblastoma: What constitutes low-risk and how low can one go?

Oncotarget | WNT-pathway medulloblastoma: What constitutes low-risk and how low can one go?
Comparison of progression-free survival (A) and overall survival (B) between children. Credit: Oncotarget (2023). DOI: 10.18632/oncotarget.28360

A new research perspective was published in Oncotarget. The paper is titled "WNT-pathway medulloblastoma: what constitutes low-risk and how low can one go?"

Novel biological insights have established that medulloblastoma is a heterogenous disease comprising four broad molecular subgroups—WNT, SHH, Group 3, and Group 4 respectively, resulting in the incorporation of molecular/ in 5th edition of WHO and contemporary risk-stratification. Concerns regarding therapy-related late in long-term survivors have led to systematic attempts at treatment de-intensification in good-risk medulloblastoma.

Given the excellent survival (>90%) of WNT-pathway medulloblastoma, prospective clinical trials have focused on optimization of therapy to balance survival versus quality of survival. The currently accepted definition of low-risk WNT-pathway medulloblastoma includes children <16 years of age with residual tumour <1.5 cm2 and no evidence of metastases. This systematically excludes adolescents and young adults who have been perceived to have worse outcomes.

In a previous study, researchers Shakthivel Mani, Abhishek Chatterjee, Archya Dasgupta, Neelam Shirsat, Sridhar Epari, Girish Chinnaswamy, and Tejpal Gupta from Homi Bhabha National Institute (HBNI) in Mumbai, India, reported long-term survival of an adolescent and young adult cohort that was largely comparable to childhood medulloblastoma.

In their current research perspective, the researchers now report on molecularly characterized WNT-subgroup patients treated between 2004–2020 with risk-stratified multi-modality therapy to identify differences between childhood (<15 years) versus adolescent and young adults (>15 years).

Credit: Impact Journals LLC

Despite modest differences in disease status at presentation and treatment modality, there were no significant differences in patterns of failure or survival between childhood versus adolescent and young adult WNT-pathway medulloblastoma. Two de-intensification trials in low-risk WNT-pathway medulloblastoma—first testing omission of upfront craniospinal irradiation and second a primary chemotherapy approach after surgery—had to be terminated prematurely due to unacceptably high relapse rates suggesting that craniospinal irradiation remains an integral component of treatment.

The presence of TP53 mutations and OTX2 gains have recently been reported as independent negative prognostic factors in a multi-institutional cohort of WNT-pathway , raising questions on eligibility of such patients for de-escalation trials.

"Concerns regarding therapy-related late toxicity have prompted systematic attempts at treatment de-intensification in good-risk MB over the last four decades. However, results of prior studies should be used to inform and guide controlled de-intensification of therapy even in low-risk and favorable biology disease. The definition of low-risk WNT-MB may need to be further refined in light of recent clinical data and newer biological information," say the researchers.

More information: Shakthivel Mani et al, WNT-pathway medulloblastoma: what constitutes low-risk and how low can one go?, Oncotarget (2023). DOI: 10.18632/oncotarget.28360

Journal information: Oncotarget

Provided by Impact Journals
Citation: WNT-pathway medulloblastoma: What constitutes low-risk and how low can one go? (2023, February 27) retrieved 22 September 2023 from
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Explore further

Carboplatin intensification shown beneficial for group 3 medulloblastoma


Feedback to editors